You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

FRα

Showing 1 - 25 of 28
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer Trial (Mirvetuximab soravtansine, Carboplatin)

Not yet recruiting
  • High Grade Ovarian Cancer
  • +2 more
  • (no location specified)
Jul 11, 2022

Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial (Mirvetuximab soravtansine plus Bevacizumab, Bevacizumab)

Recruiting
  • Ovarian Cancer
  • +2 more
  • New Orleans, Louisiana
  • +3 more
Dec 16, 2022

Ovarian Cancer, Ovarian Tumors, Ovarian Carcinoma Trial in United States (ELU001)

Recruiting
  • Ovarian Cancer
  • +68 more
  • Phoenix, Arizona
  • +8 more
Aug 18, 2022

Solid Tumor Trial in United Kingdom, United States (Farletuzumab ecteribulin)

Recruiting
  • Solid Tumor
  • Farletuzumab ecteribulin
  • Tucson, Arizona
  • +26 more
Jan 30, 2023

Breast Cancer Trial in United States (Low dose FRa vaccine, Cyclophosphamide, High dose FRa vaccine)

Completed
  • Breast Cancer
  • Low dose FRα vaccine
  • +2 more
  • Tampa, Florida
  • +10 more
Jul 15, 2021

Platinum Sensitive Ovarian Cancer, Ovarian Cancer Trial in United States (FRa peptide plus Adjuvant (GM-CSF), Adjuvant (GM-CSF)

Terminated
Has Results
  • Platinum Sensitive Ovarian Cancer
  • Ovarian Cancer
  • FRα peptide plus Adjuvant (GM-CSF)
  • Adjuvant (GM-CSF) Alone
  • Birmingham, Alabama
  • +17 more
Nov 21, 2022

Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer Trial in Worldwide (Mirvetuximab soravtansine,

Completed
  • Epithelial Ovarian Cancer
  • +2 more
  • Mirvetuximab soravtansine
  • +4 more
  • Birmingham, Alabama
  • +15 more
Dec 13, 2021

Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial in China (Mirvetuximab Soravtansine)

Recruiting
  • Epithelial Ovarian Cancer
  • +2 more
  • Mirvetuximab Soravtansine
  • Bengbu, Anhui, China
  • +27 more
Nov 14, 2022

Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial in Worldwide (Mirvetuximab Soravtansine)

Completed
  • Epithelial Ovarian Cancer
  • +2 more
  • Mirvetuximab Soravtansine
  • Phoenix, Arizona
  • +88 more
Jan 19, 2023

Ovarian Cancer, Fallopian Tube, Primary Peritoneal Cancer Trial in Birmingham (mirvetuximab soravtansine (MIRV; IMGN853))

Recruiting
  • Ovarian Cancer
  • +2 more
  • mirvetuximab soravtansine (MIRV; IMGN853)
  • Birmingham, Alabama
    University of Alabama at Birmingham Womens & Infants Center
Jun 30, 2022

CBFA2T3-GLIS2-positive Acute Myeloid Leukemia, AML, Childhood, Relapsed Pediatric AML Trial (ELU001)

Not yet recruiting
  • CBFA2T3-GLIS2-positive Acute Myeloid Leukemia
  • +3 more
  • (no location specified)
Nov 14, 2022

Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial in Worldwide (Mirvetuximab Soravtansine, Paclitaxel,

Active, not recruiting
  • Epithelial Ovarian Cancer
  • +2 more
  • Mirvetuximab Soravtansine
  • +3 more
  • Birmingham, Alabama
  • +207 more
Oct 28, 2022

Endometrial Cancer Trial in New Haven (IMGN853)

Recruiting
  • Endometrial Cancer
  • New Haven, Connecticut
    Smilow Cancer Hospital at Yale New Haven
Aug 10, 2022

Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial in Worldwide (Mirvetuximab soravtansine)

Recruiting
  • Ovarian Cancer
  • +2 more
  • Mirvetuximab soravtansine
  • Anchorage, Alaska
  • +55 more
Jul 25, 2022

Endometrial Cancer Trial in Boston, Worcester (Pembrolizumab, IMGN853)

Recruiting
  • Endometrial Cancer
  • Boston, Massachusetts
  • +2 more
Oct 24, 2022

Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer Trial (Luveltamab tazevibulin, Pegfilgrastim)

Not yet recruiting
  • Ovarian Cancer
  • +4 more
  • (no location specified)
May 12, 2023

Ovary Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial in Aurora (Mirvetuximab Soravtansine, Olaparib)

Not yet recruiting
  • Ovary Cancer
  • +2 more
  • Aurora, Colorado
    University of Colorado Hospital
May 30, 2023

Tumors Trial in Philadelphia (OTL38)

Completed
  • Neoplasms
  • Philadelphia, Pennsylvania
    Hospital of the University of Pennsylvania
Jun 27, 2022

Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer Trial in United States (PRO1184)

Recruiting
  • Ovarian Cancer
  • +8 more
  • Scottsdale, Arizona
  • +11 more
Jan 31, 2023

Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer Trial (Pegylated Liposomal Doxorubicin +

Not yet recruiting
  • Platinum-resistant Ovarian Cancer
  • +6 more
  • Pegylated Liposomal Doxorubicin + SL-172154
  • Mirvetuximab + SL-172154
  • (no location specified)
Jul 29, 2022

Lung Tumors, Lung Cancer Trial in Netherlands, United States (drug, device, procedure)

Completed
  • Lung Neoplasms
  • Lung Cancer
  • OTL38 for Injection
  • +2 more
  • Boston, Massachusetts
  • +5 more
Sep 10, 2021

Tumors, Solid Tumor Trial in Hidaka-shi, Chuo-ku (MORAb-003)

Completed
  • Neoplasms
  • Solid Tumor
  • Hidaka-shi, Saitama, Japan
  • +1 more
Jun 8, 2020

Breast Cancer Triple Negative Trial in Durham (Mirvetuximab Soravtansine (IMGN853))

Withdrawn
  • Breast Cancer Triple Negative
  • Mirvetuximab Soravtansine (IMGN853)
  • Durham, North Carolina
    Duke University Medical Center
Jul 2, 2018

Endometrial Cancer, Endometrial Adenocarcinoma, Endometrial Serous Adenocarcinoma Trial in Oklahoma City (Mirvetuximab

Withdrawn
  • Endometrial Cancer
  • +3 more
  • Oklahoma City, Oklahoma
    Stephenson Cancer Center
Jun 25, 2019

Tumors, Pituitary Tumors Trial in Philadelphia (OTL38)

Terminated
  • Neoplasms
  • Pituitary Neoplasms
  • Philadelphia, Pennsylvania
    Hospital of the University of Pennsylvania
Aug 2, 2019